We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Feasibility of Tuberculosis Test Proven in Low-Resource Settings

By LabMedica International staff writers
Posted on 10 May 2011
A molecular diagnostic test for tuberculosis (TB) has proven to be both effective and rapid in countries in the developing world that are endemic for the disease.

The assay is a real time polymerase chain reaction (rt-PCR) amplification test that simultaneously detects rifampicin resistance and is used in conjunction with an automated platform, which integrates sample processing and greatly simplifies testing.

A multicenter study is being conducted under the auspices of the Foundation for Innovative New Diagnostics (FIND; Geneva, Switzerland).

South African participants at the University of Cape Town (Cape Town, South Africa), and others from Peru, India, Azerbaijan, the Philippines, and Uganda, enrolled 6,648 eligible adults. More...
The study groups were all aged 18 years or older, with at least two weeks of cough who presented consecutively to urban or periurban primary-care health centers from August 11, 2009, until June 26, 2010. The primary impact outcomes assessed were the time between the first presentation to clinic of a patient with symptoms and the start of appropriate treatment for TB and, secondly, the proportion of patients in each site with undiagnosed TB, two months after the first TB test.

The rt-PCR assay is an automated cartridge based diagnostic system, known as the Xpert MTB/RIF, and was developed for the GeneXpert platform (Cepheid, Sunnyvale, CA, USA). The test correctly detected tuberculosis in more than 90% of patients with positive cultures, with a 99% specificity for nontuberculosis samples. Performance was much the same during validation and implementation phases. A onetime MTB/RIF test identified significantly more cases of tuberculosis than did 2-3 smear microscopy examinations per patient, which detected 699 of 1,041 culture-positive patients and 3,700 of 3,718 patients without tuberculosis. The sensitivity of the MTB/RIF assay was not significantly affected by human immunodeficiency virus (HIV) coinfection status, which significantly decreased the sensitivity of smear microscopy.

The authors concluded that overall, their findings suggest that decentralized MTB/RIF test implementation is feasible and could lead to an improvement in tuberculosis care and control. Any improvement will require increased detection of tuberculosis and multidrug-resistant-tuberculosis to coincide with scale-up of first-line, and more importantly, second-line treatment. Whether early and appropriate treatment after MTB/RIF testing can reduce tuberculosis-associated morbidity and mortality, and its effect on transmission, still needs to be established. The study was published on April 30, 2011, the Lancet.

Related Links:
Foundation for Innovative New Diagnostics
University of Cape Town
Cepheid


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more

Technology

view channel
Image: The newly designed ExoPatch successfully distinguished melanoma from healthy skin in mice (Photo courtesy of Jeremy Little/Michigan Engineering)

Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.